Antibody therapy in pancreatic cancer: mAb-ye we're onto something?
AJ Boland, AA O'Kane, R Buick, DB Longley… - Biochimica et Biophysica …, 2021 - Elsevier
Pancreatic cancer remains an extremely deadly disease, with little improvement seen in
treatment or outcomes over the last 40 years. Targeted monoclonal antibody therapy is one …
treatment or outcomes over the last 40 years. Targeted monoclonal antibody therapy is one …
A subset of new platinum antitumor agents kills cells by a multimodal mechanism of action also involving changes in the organization of the microtubule cytoskeleton
H Kostrhunova, J Zajac, V Novohradsky… - Journal of Medicinal …, 2019 - ACS Publications
The substitution inert platinum agent [Pt (1 S, 2 S-diaminocyclohexane)(5, 6-dimethyl-1, 10-
phenanthroline)] 2+(56MeSS, 5) is a potent cytotoxic metallodrug. In contrast to conventional …
phenanthroline)] 2+(56MeSS, 5) is a potent cytotoxic metallodrug. In contrast to conventional …
Probing metabolic alterations in breast cancer in response to molecular inhibitors with Raman spectroscopy and validated with mass spectrometry
Rapid and accurate response to targeted therapies is critical to differentiate tumors that are
resistant to treatment early in the regimen. In this work, we demonstrate a rapid, noninvasive …
resistant to treatment early in the regimen. In this work, we demonstrate a rapid, noninvasive …
KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer
K Shimozaki, E Shinozaki, N Yamamoto… - Journal of Cancer …, 2023 - Springer
Abstract Purpose Although RAS and PIK3CA mutations have been associated with
resistance to anti-EGFR antibody in colorectal cancer or trastuzumab in breast cancer, their …
resistance to anti-EGFR antibody in colorectal cancer or trastuzumab in breast cancer, their …
Targeted inhibition of cooperative mutation-and therapy-induced AKT activation in AML effectively enhances response to chemotherapy
M Estruch, K Reckzeh, C Vittori, A Centio, M Ali… - Leukemia, 2021 - nature.com
Most AML patients exhibit mutational activation of the PI3K/AKT signaling pathway, which
promotes downstream effects including growth, survival, DNA repair, and resistance to …
promotes downstream effects including growth, survival, DNA repair, and resistance to …
Auger emitter conjugated PARP inhibitor for therapy in triple negative breast cancers: a comparative in-vitro study
RA Sankaranarayanan, J Peil, ATJ Vogg, C Bolm… - Cancers, 2022 - mdpi.com
Simple Summary Triple negative breast cancer (TNBC) is an aggressive subtype of breast
cancer, with a high recurrence rate. Since treatment of BRCAmut TNBC patients with PARP …
cancer, with a high recurrence rate. Since treatment of BRCAmut TNBC patients with PARP …
A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
Y Yan, X Cheng, L Li, R Zhang, Y Zhu, Z Wu… - Frontiers in …, 2021 - frontiersin.org
Breast cancer is the most common malignant cancer in women worldwide, especially in
developing countries. Herceptin is a monoclonal antibody with an antitumor effect in HER2 …
developing countries. Herceptin is a monoclonal antibody with an antitumor effect in HER2 …
[HTML][HTML] PIK3CA mutation is associated with poor response to HER2-targeted therapy in breast cancer patients
JW Kim, AR Lim, JY You, JH Lee… - … : Official Journal of …, 2023 - synapse.koreamed.org
Purpose Mutations in the PIK3CA gene occur frequently in breast cancer patients. Activating
PIK3CA mutations confer resistance to human epidermal growth factor receptor 2 (HER2) …
PIK3CA mutations confer resistance to human epidermal growth factor receptor 2 (HER2) …
Data-driven information extraction and enrichment of molecular profiling data for cancer cell lines
E Smith, R Paloots, D Giagkos, M Baudis… - Bioinformatics …, 2024 - academic.oup.com
Motivation With the proliferation of research means and computational methodologies,
published biomedical literature is growing exponentially in numbers and volume. Cancer …
published biomedical literature is growing exponentially in numbers and volume. Cancer …
The LCLAT1/LYCAT acyltransferase is required for EGF-mediated phosphatidylinositol-3, 4, 5-trisphosphate generation and Akt signaling
V Chan, C Camardi, K Zhang… - Molecular Biology of …, 2024 - molbiolcell.org
Receptor tyrosine kinases such as EGF receptor (EGFR) stimulate phosphoinositide 3
kinases to convert phosphatidylinositol-4, 5-bisphosophate [PtdIns (4, 5) P2] into …
kinases to convert phosphatidylinositol-4, 5-bisphosophate [PtdIns (4, 5) P2] into …